By Rightful Advice 
Empower Pharmacy, a major Houston-based compounding pharmacy and outsourcing facility, faces ongoing regulatory scrutiny and litigation as of April 2026. The primary legal development involves a federal lawsuit filed by Eli Lilly and Company alleging unauthorized compounding and marketing of tirzepatide-based drugs. This case, combined with multiple FDA warning letters issued in April 2025 and subsequent state-level enforcement actions, raises important questions about compliance with federal drug safety standards for compounded medications.
These matters affect patients relying on compounded drugs, healthcare providers prescribing them, and the broader compounding pharmacy industry. The developments underscore the intersection of FDA oversight under the Federal Food, Drug, and Cosmetic Act (FDCA) and private litigation over drug marketing practices. This article provides a factual overview based on public court records, FDA documents, and regulatory announcements. It explains the key issues without speculating on outcomes.
Background & Legal Context
Compounding pharmacies prepare customized medications for individual patients when commercially available drugs do not meet specific needs. Congress addressed safety concerns following the 2012 New England Compounding Center outbreak through the Drug Quality and Security Act (DQSA) of 2013. This law created Section 503A for traditional compounding pharmacies (patient-specific prescriptions) and Section 503B for outsourcing facilities that produce larger batches under current good manufacturing practice (CGMP) standards.
Outsourcing facilities registered under Section 503B receive exemptions from certain FDCA requirements, including premarket approval, but must comply with strict sterility, labeling, and quality controls for drugs intended or expected to be sterile. Violations can render products adulterated or misbranded, exposing facilities to enforcement actions.
Empower Clinic Services, LLC, doing business as Empower Pharmacy, operates facilities in Houston, Texas, and has registered one as a 503B outsourcing facility since 2016. The company has faced FDA inspections and prior warning letters dating back to 2017, highlighting recurring themes such as environmental monitoring, aseptic processing, and batch release protocols.
Key Legal Issues Explained
The core issues in the Empower Pharmacy lawsuit and related regulatory actions center on three areas:
- Sterility and CGMP Compliance: Sterile injectable drugs must be produced in controlled environments to prevent microbial contamination. FDA regulations under 21 CFR Part 211 require validated aseptic processes, thorough investigations of deviations (such as positive microbial results), and proper equipment sterilization. Failure to meet these can classify drugs as adulterated under FDCA Section 501(a)(2)(A) or (B).
- Section 503B Exemptions and Labeling: For 503B facilities, drugs must include specific labeling (for example, adverse event reporting information and directions for use) to qualify for exemptions from new drug approval and adequate directions requirements. Without compliance, products become unapproved new drugs and misbranded under FDCA Sections 505 and 502(f)(1).
- Marketing and Consumer Protection Claims: The Eli Lilly lawsuit invokes the Lanham Act (trademark and false advertising) and state consumer fraud statutes. It alleges that compounded versions of approved drugs, when produced at scale outside shortage conditions or without proper disclaimers, mislead consumers about safety, efficacy, and regulatory status.
These concepts stem from established FDA frameworks designed to protect public health while allowing access to compounded therapies. Courts evaluate such claims through motions to dismiss or summary judgment, focusing on whether pleadings meet federal pleading standards under Rule 12(b)(6) of the Federal Rules of Civil Procedure.
Latest Developments or Case Status
In April 2025, the FDA issued two warning letters (WL #700964 and WL #700962) following inspections of Empower’s Houston facilities in August through October 2024. The letters cited insanitary conditions for sterile drug production, including inadequate environmental monitoring in ISO 5 areas, media fills not performed under worst-case conditions, and failure to sterilize critical equipment such as stopper sorting bowls. One facility released a pyridoxine HCl injection batch despite microbial recovery in the aseptic area; the company later recalled the lot.
Follow-up reporting in January 2026 noted repeat observations during a subsequent inspection, including contamination risks in testosterone production areas and inadequate cleaning validation. Empower responded to the FDA with corrective action plans, including updated procedures and third-party assessments, but the agency continued to express concerns about oversight.
Separately, Eli Lilly filed suit against Empower on April 1, 2025, in the U.S. District Court for the District of New Jersey (Case No. 2:25-cv-02183). The complaint alleged Empower engaged in large-scale compounding of tirzepatide formulations (active ingredient in Lilly’s Mounjaro and Zepbound) after the FDA resolved related shortages, using misleading marketing that referenced Lilly’s clinical data. Lilly claimed violations of the Lanham Act and New Jersey Consumer Fraud Act. The case was voluntarily dismissed and refiled in the U.S. District Court for the Southern District of Texas on July 25, 2025 (Case No. 4:25-cv-03464). Empower filed a motion to dismiss in October 2025, arguing the claims fall outside private enforcement and constitute anticompetitive conduct. As of April 2026, the motion remains pending with no trial date set.
In parallel, the California State Board of Pharmacy, where Empower holds a nonresident sterile compounding permit on probation since 2022, moved in late 2025 to revoke probation based on new charges. Records cite patient reports of adverse events (including gastrointestinal issues and infections) linked to compounded drugs, use of ingredients from suppliers not properly registered with the FDA, and dispensing practices involving GLP-1 medications. Texas regulators have also documented additional violations.
Who Is Affected & Potential Impact
Patients using compounded sterile injectables, particularly for weight management, hormone therapy, or nutritional support, may face heightened safety considerations if quality controls lapse. Healthcare providers and clinics sourcing from Empower must verify product labeling and compliance status. The compounding industry as a whole monitors these cases because outcomes could influence FDA enforcement priorities and private litigation strategies against mass compounders.
Businesses operating as 503A or 503B facilities could see increased inspection frequency or stricter state licensing requirements. Potential consequences include product recalls, restricted distribution, or, in extreme cases, injunctions against specific operations. No findings of widespread patient harm have been confirmed by the FDA in its letters, but state actions reference individual adverse event reports.
What This Means Going Forward
These developments highlight the FDA’s continued focus on sterile compounding safety post-DQSA. They also illustrate how brand-name manufacturers may use consumer protection laws to address perceived market erosion from compounded alternatives once shortages end. Readers should monitor federal court dockets for rulings on the dismissal motion and FDA updates on warning letter close-outs. State pharmacy boards provide public disciplinary records that offer additional transparency.
Industry stakeholders, including the Outsourcing Facilities Association, have noted that clear FDA guidance on bulk substances and shortage determinations remains critical for compliance. Patients and prescribers are advised to consult licensed providers and review product labeling directly.
Frequently Asked Questions
What is the Empower Pharmacy lawsuit primarily about?
The lawsuit refers to Eli Lilly and Company’s federal action alleging that Empower unlawfully compounded and marketed tirzepatide-containing products on a commercial scale, violating false advertising and consumer protection laws. The case was refiled in Texas federal court in July 2025 and remains ongoing.
What did the April 2025 FDA warning letters address?
The letters detailed deficiencies in sterile drug production practices at two Houston facilities, including insanitary conditions, inadequate investigations of microbial excursions, equipment sterilization failures, and labeling omissions that disqualified 503B exemptions. Products were deemed potentially adulterated or misbranded.
How do these FDA warnings affect compounded drug availability?
Warnings do not automatically halt operations but signal the need for corrective actions. Facilities must address cited issues or risk further enforcement, such as product seizures or injunctions. Patients should confirm with prescribers whether alternative sources are advisable during remediation.
Has Empower faced similar issues before 2025?
Yes. Public FDA records show prior warning letters in 2017 and 2021, plus state probation in California since 2022. Investigations have documented recurring themes in quality assurance and sterility controls over more than a decade.
What should patients do if they received compounded drugs from Empower?
Review any provided labeling for adverse event reporting instructions. Report any side effects to the prescriber, the pharmacy, or the FDA’s MedWatch program. Consult a healthcare provider regarding continued use or testing needs.
Could the Eli Lilly case set a precedent for other compounding pharmacies?
If it proceeds past the motion to dismiss, the case could clarify the boundaries of private lawsuits under the Lanham Act against compounders of drugs similar to approved products. However, FDA retains primary authority over safety and approval issues.
Conclusion
The Empower Pharmacy lawsuit and accompanying FDA warnings reflect ongoing efforts to balance innovation in personalized medicine with rigorous safety standards under the FDCA. As the Texas federal case advances and state regulators pursue enforcement, the developments serve as a reminder of the importance of verifiable compliance in pharmaceutical compounding. Stakeholders should continue reviewing official FDA and court sources for verified updates. This article is for informational purposes only and does not constitute legal advice. Individuals should consult qualified legal or healthcare professionals for advice specific to their circumstances.
You may also like: T14 Law Schools: 2026-2027 Rankings & Admissions Guide